title: Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
authors.affiliation: Department of Neurology, University Hospital Zurich , Zurich , Switzerland.
authors.forename: Michaela
authors.initials: M
authors.lastname: Tonder
authors.forename: Günter
authors.initials: G
authors.lastname: Eisele
authors.forename: Tobias
authors.initials: T
authors.lastname: Weiss
authors.forename: Silvia
authors.initials: S
authors.lastname: Hofer
authors.forename: Katharina
authors.initials: K
authors.lastname: Seystahl
authors.forename: Antonios
authors.initials: A
authors.lastname: Valavanis
authors.forename: Roger
authors.initials: R
authors.lastname: Stupp
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
authors.forename: Patrick
authors.initials: P
authors.lastname: Roth
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D018450:Disease Progression; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D008130:Lomustine